Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets remain buoyant
Fri, 31 Jan 01:30 pm

Indian share markets continued to trade higher in the post-noon trading session. Barring auto, consumer durable and pharma, all the sectoral indices are trading in the green with realty, IT and metal stocks being the biggest gainers.

BSE-Sensex is up 28 points and NSE-Nifty is trading 16 points up. BSE Mid Cap is trading 1.1% up and BSE Small Cap index is trading up by 1.2%. The rupee is trading at 62.5 to the US dollar.

Majority of the Indian pharma stocks are trading in the green with Panacea Biotech and Dishman Pharma being among major gainers.Sun Pharma and IPCA Labs are the few stocks trading in the red. As per a leading financial daily, Cadila Healthcare has received the final approval for an arthritis drug from US Food and Drug Administration (USFDA). The company has received the final approval to market Etodolac Extended-release Tablets in strengths of 400 mg, 500 mg and 600 mg. The drug is prescribed for the treatment of juvenile arthritis, rheumatoid arthritis and osteoarthritis. Cadila Healthcare has 88 approvals and has filed 216 Abbreviated New Drug Applications (ANDAs) so far after the commencement of the filing process in FY04.

Engineering stocks are trading mixed today. While Welspun Corporation and Punj Lloyd are trading on a positive note, Alstom Projects and Emco Ltd. are trading in the red. As per a leading business daily, empowered group of ministers (EGoM) has approved the nod for the follow-on-public (FPO) offer of Engineers India (EIL). The ministries nod for the offer took over a year after the approval from the Cabinet Committee of Economic Affairs. The government which holds 80.4% stake in EIL, intends to offer its 10% stake in the FPO. At EIL's current market price government would fetch not more than Rs 5 bn through the offer. The offer would now await the registrar of companies nod for further process. This stake sale is a part of the government divestment plan where it intends to raise about Rs 400 bn by divestment and another Rs 140 bn through residual stake sale in non-government entities during the current fiscal. Till now, the government has only raised about Rs 30 bn through stake sale in PSU. Divestment in Indian Oil Corporation, BHEL, Hindustan Zinc and Axis Bank are also in the offing.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.